Erasca Q2 2025 net loss $33.9M; cash $386.7M; INDs cleared for two RAS drugs

Erasca, Inc.

2025-Q2 EPS reported -$0.23 vs consensus -$0.11 ▼ miss (-105.0%)

Net loss of $33.9M ($0.12/sh) for Q2 2025, down from $63.2M ($0.29/sh) in Q2 2024.
Cash, equivalents, and marketable securities $386.7M as of June 30, 2025; expected to fund operations into H2 2028.
IND cleared for pan-KRAS inhibitor ERAS-4001 (Jun 2025) and pan-RAS molecular glue ERAS-0015 (May 2025); Phase 1 trials ongoing.
Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.
R&D expenses $21.2M in Q2 2025 vs $33.0M in Q2 2024, driven by lower impairment and personnel costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.